Here is what I’m reading this morning:
- Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks
- Pharma R&D Investments Moderating — But Still High
- R&D Is Time Consuming and Expensive. Robotics, 3D Printing, & AR/VR Are Changing That.
- Fixing the Clinical Trial Bottleneck by Making Patients a Priority